Cancer Institute A national cancer institute
designated cancer center

Youn H Kim

Publication Details

  • Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Kim, Y. H., Girardi, M., Duvic, M., Kuzel, T., Link, B. K., Brown, L. P., Rook, A. H. 2010; 63 (6): 975-983

    Abstract:

    Mycosis fungoides and Sézary syndrome are a class of lymphomas of skin-trafficking T cells, and they are the most common forms of cutaneous T-cell lymphoma (CTCL). Mycosis fungoides and Sézary syndrome are chronic, frequently incurable diseases with limited therapeutic options. PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer.This study was conducted to determine the safety and tolerability of single-agent PF-3512676 in patients with CTCL.In this phase I dose-escalation study, patients (N = 28) with treatment-refractory, stage IB to IVA CTCL were enrolled in 6 sequential cohorts and treated with PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections. Primary end points were safety and tolerability.Common adverse events (fatigue, rigors, injection-site reactions, myalgia, lymphopenia, leukopenia, neutropenia, and pyrexia) were mostly grade 1 or 2, and no patient developed specific symptoms associated with autoimmune disease. Clinical response rate to PF-3512676, as determined by both Composite Assessment of Index Lesion Severity and Physician Global Assessment, was 32% (3 complete clinical responses, 6 partial responses); the majority of responses (7/9; 78%) were ongoing at the end of study.This trial was not designed to rigorously assess efficacy.Single-agent PF-3512676 was well tolerated and demonstrated antitumor activity in patients with refractory CTCL.

    View details for DOI 10.1016/j.jaad.2009.12.052

    View details for Web of Science ID 000284968100003

    View details for PubMedID 20888065

Stanford Medicine Resources:

Footer Links: